Enterprise Value
196M
Cash
296.2M
Avg Qtr Burn
-36.57M
Short % of Float
20.67%
Insider Ownership
0.34%
Institutional Own.
81.08%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Reni-cel (renizgamglogene autogedtemcel) (EDIT-301) Details Sickle cell disease, Genetic disorder | Phase 1/2 Data readout | |
Reni-cel (renizgamglogene autogedtemcel) (EDIT-301) Details Genetic disorder, Beta thalessemia | Phase 1/2 Data readout | |
EDIT-101 Details Rare diseases, Eye disease , Rare genetic disease, Hepatitis C | Failed Discontinued |